Two decades since the first demonstration that 5-fluorouracil (5-FU)-based adjuvant chemotherapy improves survival in resected colon cancer,1 the standard of care of adjuvant chemotherapy in this disease has been shaped by several pivotal phase III trials and meta-analyses.2,3 Adjuvant treatment still relies on a fluoropyrimidine backbone (5-FU/FA (folinic acid) or capecitabine) with the addition of oxaliplatin for stage III colon cancers and select stage II cancers to form the FOLFOX, XELOX, or...